A recent study led by Francesco Oddone at IRCCS Fondazione Bietti in Rome evaluated a preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. The results indicated a significant decrease in intraocular pressure over a full 24-hour period, alongside improvements in ocular surface disease signs and symptoms. The study also addressed corneal and conjunctival health, OSD symptoms, and quality of life using validated tools. The findings suggest that preservative-free fixed combinations may provide improved IOP control as well as alleviate signs and symptoms of OSD caused by the treatment.

Source: Clinical Ophthalmology